RxDoctor Payments Data

Conrado Ordonez, MD

Internal Medicine · Rosenberg, TXNPI 1124225453

Payments from drug & device makers

$2,495in general payments, 2019–2025

Across 137 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$612
  • Lilly USA, LLC$601
  • AstraZeneca$362
  • Amgen$272
  • AbbVie$124
  • Sanofi-aventis U.S. LLC$110
  • plus $415 from 7 others

What the payments were for

  • Food & beverage$2,495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,495 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$14,395
Medicare patients
54
Services billed
288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$46,140
JanuviaSitagliptin Phosphate37$44,690
OzempicSemaglutide21$42,557
TrulicityDulaglutide22$40,955
FarxigaDapagliflozin Propanediol26$33,629
TradjentaLinagliptin17$21,263
LinzessLinaclotide16$18,643
Tresiba Flextouch U-200Insulin Degludec13$13,363
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,236
Tresiba Flextouch U-100Insulin Degludec12$9,076
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$8,938
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,016
Alcohol PadsAlcohol Antiseptic Pads21$2,112
Atorvastatin Calcium254$2,006
Albuterol Sulfate HfaAlbuterol Sulfate50$1,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$82$67,40351 claims
MerckJanuvia$72$44,69037 claims
Novo NordiskOzempic$612$42,55721 claims
Lilly USA, LLCTrulicity$601$40,95522 claims
AstraZenecaFarxiga$362$33,62926 claims
AbbVieLinzess$124$18,64316 claims
GSKTrelegy Ellipta$53$12,23616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Rosenberg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →